IPP Bureau
Dr. Bharati Pravin Pawar launches Intensified Diarrhoea Control Fortnight – 2022
By IPP Bureau - June 14, 2022
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Philips announces positive research results from its TOBA II BTK clinical trial
By IPP Bureau - June 14, 2022
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
.png "Thermo Fisher Scientific launches new MS-based solutions")
Thermo Fisher Scientific launches new MS-based solutions
By IPP Bureau - June 14, 2022
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
By IPP Bureau - June 14, 2022
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma
By IPP Bureau - June 14, 2022
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants
By IPP Bureau - June 14, 2022
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Karkinos Healthcare launched ‘Advanced Center for Cancer Diagnostics and Research’
By IPP Bureau - June 12, 2022
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
By IPP Bureau - June 12, 2022
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Alembic receives USFDA tentative approval for Dasatinib tablets
By IPP Bureau - June 12, 2022
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Strides receives USFDA approval for Ibuprofen OTC oral suspension
By IPP Bureau - June 12, 2022
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis
By IPP Bureau - June 12, 2022
Amarex Clinical Research guides its client to phase II of FDA trials
Isotopia and CPDC deliver first doses of n.c.a. Lu-177 to North American customers
By IPP Bureau - June 12, 2022
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Cantourage and Clever leaves intensify partnership for distribution of medical cannabis in Germany
By IPP Bureau - June 12, 2022
Cantourage introduces second Clever Leaves medical cannabis product to the German market
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
By IPP Bureau - June 12, 2022
Tislelizumab is now approved in nine indications in China
Modi Inaugurates hospital complex and CoE in South Gujarat
By IPP Bureau - June 11, 2022
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
